Peptides Codex
Home
Cyclic lipopeptide antibiotic

Polymyxin B

Polymyxin B is a cyclic lipopeptide antibiotic from Paenibacillus polymyxa, produced as a mixture of closely related components. Its cationic diaminobutyric acid residues bind the lipid A of lipopolysaccharide, permeabilizing the Gram-negative outer membrane. Approved since 1964 and on the WHO Essential Medicines List, it is used for serious Gram-negative infections and in topical combinations. This page is educational and not medical advice.

By The Peptides Codex Editorial TeamReviewed July 10, 2026
Length
n/a
Class
Cyclic lipopeptide antibiotic
Function
Binds lipopolysaccharide and disrupts the Gram-negative outer membrane
Context
Approved antibiotic for serious Gram-negative infections; also in topical products

A last-line polycationic lipopeptide that targets lipid A of Gram-negative bacteria; on the WHO Essential Medicines List.

Also known as: PMB

Part of the Foundational & therapeutic peptides cluster

Overview

Polymyxin B is a cyclic lipopeptide antibiotic from Paenibacillus polymyxa, produced as a mixture of closely related components. Its cationic diaminobutyric acid residues bind the lipid A of lipopolysaccharide, permeabilizing the Gram-negative outer membrane. Approved since 1964 and on the WHO Essential Medicines List, it is used for serious Gram-negative infections and in topical combinations. This page is educational and not medical advice.

Source & context

Biological / chemical source: Soil bacterium Paenibacillus polymyxa (formerly Bacillus polymyxa)

Primary research or clinical context: Approved antibiotic for serious Gram-negative infections; also in topical products

Structure and mechanism

Polymyxin B is a cyclic heptapeptide with a tripeptide side chain bearing a fatty-acyl tail and several 2,4-diaminobutyric acid (Dab) residues. The positively charged Dab groups bind anionic lipid A, displacing stabilizing cations and dissolving into the membrane so that it leaks. It is inactive against Gram-positive bacteria.

Clinical role

Once limited by kidney and nerve toxicity, polymyxin B re-emerged as a treatment for multidrug-resistant Gram-negative infections such as those from Pseudomonas aeruginosa. It also appears in over-the-counter topical antibiotic ointments alongside bacitracin and neomycin. Systemic use requires clinical supervision.

FAQ about Polymyxin B

What is Polymyxin B?+

Polymyxin B is a cyclic lipopeptide antibiotic from Paenibacillus polymyxa, produced as a mixture of closely related components. Its cationic diaminobutyric acid residues bind the lipid A of lipopolysaccharide, permeabilizing the Gram-negative outer membrane. Approved since 1964 and on the WHO Essential Medicines List, it is used for serious Gram-negative infections and in topical combinations. This page is educational and not medical advice.

Is Polymyxin B an approved medicine?+

Polymyxin B: Approved antibiotic for serious Gram-negative infections; also in topical products. Always follow licensed medical guidance for approved products.

What is the typical length of Polymyxin B?+

Polymyxin B is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.

Related peptides

References & further reading

  1. 1.Wikipedia — Polymyxin B
  2. 2.PubChem — compound summary for Polymyxin B (CID 49800004)
Disclaimer: Educational content only. Not medical advice. Not instructions for human use. Research peptides and unapproved products may be restricted or illegal to market for human consumption in your jurisdiction. Consult qualified professionals and applicable law.
You might also like: All peptides · Atlas · Research · Tools
Cite this: Peptides Codex — Polymyxin B educational profile.
Tip: Use browser print (Ctrl/Cmd + P) for a clean PDF of this page.